795 reports of this reaction
2.8% of all CLOTRIMAZOLE TOPICAL reports
#2 most reported adverse reaction
MACULAR DEGENERATION is the #2 most commonly reported adverse reaction for CLOTRIMAZOLE TOPICAL, manufactured by Novitium Pharma LLC. There are 795 FDA adverse event reports linking CLOTRIMAZOLE TOPICAL to MACULAR DEGENERATION. This represents approximately 2.8% of all 28,521 adverse event reports for this drug.
Patients taking CLOTRIMAZOLE TOPICAL who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is a less commonly reported adverse event for CLOTRIMAZOLE TOPICAL, but still significant enough to appear in the safety profile.
In addition to macular degeneration, the following adverse reactions have been reported for CLOTRIMAZOLE TOPICAL:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 795 FDA reports for CLOTRIMAZOLE TOPICAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 2.8% of all adverse event reports for CLOTRIMAZOLE TOPICAL, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking CLOTRIMAZOLE TOPICAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.